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Soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), in contrast
to membrane TWEAK and TNF, is only a weak activator of the classical NFκB pathway.
We observed that soluble TWEAK was regularly more potent than TNF with respect to
the induction ofTNF receptor-associated factor 1 (TRAF1), a NFκB-controlled signaling pro-
tein involved in the regulation of inflammatory signaling pathways. TNF-induced TRAF1
expression was efficiently blocked by inhibition of the classical NFκB pathway using the
IKK2 inhibitor,TPCA1. In contrast, in some cell lines,TWEAK-inducedTRAF1 production was
only partly inhibited byTPCA1.The NEDD8-activating enzyme inhibitor MLN4924, however,
which inhibits classical and alternative NFκB signaling, blocked TNF- and TWEAK-induced
TRAF1 expression. This suggests that TRAF1 induction by soluble TWEAK is based on the
cooperative activity of the two NFκB signaling pathways. We have previously shown that
oligomerization of soluble TWEAK results in ligand complexes with membrane TWEAK-
like activity. Oligomerization of soluble TWEAK showed no effect on the dose response
of TRAF1 induction, but potentiated the ability of soluble TWEAK to trigger production of
the classical NFκB-regulated cytokine IL8. Transfectants expressing soluble TWEAK and
membrane TWEAK showed similar induction of TRAF1 while only the membrane TWEAK
expressing cells robustly stimulated IL8 production.These data indicate that solubleTWEAK
may efficiently induce a distinct subset of the membraneTWEAK-targeted genes and argue
again for a crucial role of classical NFκB pathway-independent signaling inTWEAK-induced
TRAF1 expression. Other TWEAK targets, which can be equally well induced by soluble
and membrane TWEAK, remain to be identified and the relevance of the ability of soluble
TWEAK to induce such a distinct subset of membrane TWEAK-targeted genes for TWEAK
biology will have to be clarified in future studies.
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INTRODUCTION
Tumor necrosis factor (TNF)-like weak inducer of apopto-
sis (TWEAK) and fibroblast growth factor (FGF)-inducible
molecule-14 (Fn14), alternatively termed TweakR or TNFRSF12,
form a phylogenetically well conserved ligand–receptor pair of the
TNF family. Fn14 is highly expressed during development and in
cancer but is also strongly induced in a variety of cell types of
the adult organism upon tissue damage (1, 2). Accordingly, Fn14
has been implicated in tissue repair-associated processes, such as
control of proliferation and differentiation of mesenchymal prog-
enitor cells, orchestration of immune reactions, cell migration,
and angiogenesis. However, if not held in check, Fn14 activity
can also have detrimental effects contributing to autoimmune-
related pathologies but also to muscle atrophy, ischemic tissue
damage, and fibrosis (1, 2). Typically, stimulation of Fn14 results
in the activation of various proinflammatory signaling path-
ways such as the classical and alternative NFκB pathway and
the various MAPK pathways (3, 4). Like most other members
of the TNF receptor family, Fn14 activates proinflammatory sig-
naling pathways with the help of adapter proteins of the TNF
receptor-associated factor (TRAF) family, especially TRAF2 (5–
7). Indeed, TRAF2 and the TRAF2-associated E3 ligases cellular
inhibitor of apoptosis-1 (cIAP1) and cIAP2 are not only required
by Fn14 for the activation of the classical NFκB pathway but are
also crucially involved in TWEAK-induced stimulation of MAP
kinases (4, 8). There is furthermore evidence that TRAF2 is also
required for TWEAK/Fn14-mediated activation of Rho-GTPases
by recruiting the Src homology 3 domain-containing guanine
nucleotide exchange factor [SGEF; (9)]. Noteworthy, TWEAK-
induced activation of Rho-GTPases appears particularly relevant
for cell migration of glioblastoma cells (9–11). In general, however,
the question how the various Fn14-associated signaling pathways
contribute, in which cell type, to the aforementioned biological
effects of TWEAK and Fn14 is poorly understood. Indeed, the
complexity of Fn14 signaling is particularly surprising against the
background of the simple structure of the molecule. Two major
mechanisms that contribute to the plasticity and variability of
TWEAK/Fn14-mediated effects are based on the capability of Fn14
to adopt different states of activity and to modulate signaling by
other members of the TNF receptor family.
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Like other members of the TNF ligand family, TWEAK acts as
a membrane-bound trimeric protein but also in a soluble form
that is released from the membrane-bound molecule by prote-
olytically processing (12–15). It is noteworthy that the two forms
of TWEAK trigger partly different patterns of intracellular signal-
ing events. So far investigated, membrane TWEAK or oligomer-
ized soluble TWEAK, which mimics the activity of membrane
TWEAK, efficiently activate all known Fn14-associated signaling
pathways including the classical NFκB pathway and proteolytic
degradation of TRAF2 (15–17). Soluble TWEAK, however, fails
to trigger these responses or does it only very moderately (15).
Membrane and soluble TWEAK, however, are both comparably
effective with respect to activation of the alternative NFκB pathway
and enhancement of TNFR1-mediated cell death (15, 17). The dif-
ferent activity of soluble and membrane TWEAK correlates with
a different effect on complexes of TRAF2 with cIAP1 or cIAP2.
Both forms of TWEAK induce efficient interaction of Fn14 with
TRAF2–cIAP1/2 complexes. However, in addition to this, Fn14
also triggers transactivation of the TRAF2-associated cIAPs and
thus activation of the classical NFκB pathway, TRAF2 degrada-
tion, and cIAP autodegradation when stimulated by membrane
TWEAK or oligomerized soluble TWEAK. The sole recruitment
of TRAF2–cIAP1/2 complexes to Fn14 is typically sufficient to
reduce the cytosolic pool of TRAF2–cIAP1/2 complexes (16, 17).
The cytosolic pool of TRAF2–cIAP1/2 complexes, however, is cru-
cially involved in the constitutive inhibition of the alternative
NFκB pathway and also antagonizes caspase-8 activation upon
TNFR1 stimulation (2). Thus, TWEAK-induced Fn14-mediated
depletion of cytosolic TRAF2–cIAP1/2 complexes, irrespective of
subsequent cIAP1/2 activation, can adequately explain the sim-
ilar activity of soluble and membrane TWEAK regarding acti-
vation of the alternative NFκB pathway and sensitization for
TNF-induced cell death. As TRAF2–cIAP1/2 complexes are also
of relevance for classical NFκB signaling and MAPK activation in
response to stimulation of various members of the TNF recep-
tor family, TRAF2–cIAP1/2 depletion is presumably also respon-
sible for the attenuated proinflammatory activities of TNFR1,
TNFR2, and CD40 that has been observed in TWEAK-primed
cells (17, 18–20).
TNF receptor-associated factor 1 forms heterocomplexes with
TRAF2 at the expense of the formation of TRAF2 homotrimers
(21). As TRAF1 and TRAF2 can differ in their affinity for the
TRAF2 binding site of a particular TRAF2-interacting TNF recep-
tor, TRAF1–TRAF2 heteromer formation can modify TRAF2-
mediated TNF receptor signaling by changing the efficacy/strength
of receptor–TRAF2 interaction. Indeed, the TNF receptor fam-
ily member CD40 recruits TRAF2–TRAF1 heteromers less effi-
cient than TRAF2 homotrimers and this correlates with reduced
activation of the classical NFκB pathway (22). TRAF1 is fur-
thermore a well-established target of classical NFκB-stimulating
cytokines, such as TNF and IL1. In light of a possible role of
TRAF1 in the crosstalk of Fn14 with other TRAF2-interacting
receptors and against the background of the different effects of
soluble and membrane TWEAK on the alternative and classical
NFκB pathway, we evaluated here the ability of different forms
of TWEAK to induce TRAF1 expression. Unexpectedly, we found
that soluble TWEAK, which poorly stimulates the classical NFκB
pathway, induces strong TRAF1 expression in transformed and
non-transformed cells. We furthermore obtained initial evidence
that soluble TWEAK-induced TRAF1 expression contributes to
the ability of the TWEAK/Fn14 system to modulate the activity of
CD40 signaling.
RESULTS
SOLUBLE TWEAK IS SUPERIOR TO TNF IN TRAF1 INDUCTION
The capabilities of soluble TNF and soluble TWEAK to activate
the classical NFκB pathway were analyzed in various cell lines. As
expected, TNF efficiently triggered phosphorylation and degrada-
tion of IκBα, two hallmarks of the classical NFκB pathway, in all cell
lines investigated within 5–15 min including transformed cell lines
of different origin (Figure 1A) and primary cells (Figure S1 in Sup-
plementary Material). In contrast, in the 2-h time window inves-
tigated, soluble TWEAK showed only delayed barely detectable
IκBα phosphorylation and IκBα degradation was practically not
evident (Figure 1A). This furthermore correlated with the fact
that production of IL8, a cytokine that is dominantly regulated by
the classical NFκB pathway, was much stronger induced by TNF
than by soluble TWEAK (Figure 1B; Figure S1 in Supplementary
Material).
To rule out that the observed limited effects of soluble TWEAK
were related to a general poor TWEAK responsiveness of the cell
lines investigated or low specific activity of the soluble TWEAK
batch used for stimulation, we also assayed activation of the
alternative NFκB pathway. Indeed, already at low concentrations
soluble TWEAK triggered accumulation of the NFκB inducing
kinase (NIK) and processing of p100, two events indicative for
stimulation of the alternative NFκB pathway (23), while TNF had
no effect in this regard (Figures 2A,B). We also analyzed induction
of TRAF1, a well-recognized NFκB-regulated target of TNF (24–
26). According to the literature, there was only weak expression
of TRAF1 in unstimulated cells, but TRAF1 expression was read-
ily induced by treatment with TNF. Surprisingly, however, soluble
TWEAK was as efficient as, or even superior to TNF in TRAF1
induction (Figures 2A,B; Figure S1 in Supplementary Material).
Although, soluble TWEAK-induced TRAF1 expression with some-
what slower kinetics than TNF, the maximal TRAF1 levels reached
were regularly significantly higher (Figures 2A,B). Noteworthy,
soluble TWEAK-induced TRAF1 production occurred with some
delay with respect to NIK accumulation and p100 processing.
(Figures 2A,B). NIK and IKK1 can also crosstalk into the clas-
sical NFκB pathway, e.g., at the level of IκBα phosphorylation
(27). We thus re-analyzed phosphorylation of IκBα in the sam-
ples of, in comparison to Figure 1A, the extended time course
used for evaluation of TRAF1 induction and activation of the
alternative NFκB pathway. Indeed, there was now significant phos-
phorylation of IκBα in soluble TWEAK-treated cells (Figure 2B).
However, analysis of total IκBα levels showed no major changes in
the amount of this molecule and there was only a minor fraction
of the slower migrating phosphorylated IκBα species. As the gene
encoding IκBα itself is a bona fide target of the classical NFκB
pathway, this argues for weak but persistent stimulation of the
downstream steps of the classical NFκB pathway resulting in a
balance between degradation and resynthesis of IκBα. However,
as soluble TWEAK, in contrast to TNF, failed to trigger robust
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FIGURE 1 |TNF is superior to solubleTWEAK in activation of the classical
NFκB pathway. (A) The various cell lines were stimulated for the indicated
times with Flag-TNF (100 ng/ml) and Flag-TWEAK (200 ng/ml) and total cell
lysates were then analyzed for the presence of phospho-IκBα and total IκBα.
(B). Cells were challenged overnight in triplicates with the indicated
concentrations of Flag-TNF and Flag-TWEAK and supernatants were assayed
for IL8 by ELISA. 786-O cells display strong constitutive expression of IL8 and
were thus not assayed for IL8 production.
production of IL8 (Figure 1B), this hardly explains the superior
induction of TRAF1 by soluble TWEAK.
One possible explanation for the observation that the capabili-
ties of TNF and soluble TWEAK to trigger the classical NFκB path-
way does not correlate with the TRAF1 expression levels induced
by these ligands is that in the case of TNF, the accumulation of
TRAF1 is limited by post-translational mechanisms. Indeed, it has
been reported that TRAF1 can be processed at D163 by caspase-
3 and caspase-8 in death receptor-stimulated cells resulting in a
NFκB inhibitory fragment (28–30). Thus, this mechanism could
possibly not only reduce the amount of TRAF1 full-length mol-
ecules but could also terminate sustained TRAF1 induction via
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FIGURE 2 | SolubleTWEAK is superior toTNF inTRAF1 induction.
(A,B) Cells were either stimulated overnight with the indicated
concentrations of Flag-TWEAK and Flag-TNF (A) or were incubated with a
constant amount of these cytokines (100 ng/ml Flag-TNF, 200 ng/ml
Flag-TWEAK) for varying times (B). Total cell lysates were finally analyzed by
western blotting with respect to the indicated proteins.
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the classical NFκB pathway. There is furthermore evidence that
cIAP2-mediated ubiquitination of TRAF1 results in proteasome-
dependent degradation (31). Thus, to evaluate the possibility that
differences in the post-translational regulation of TRAF1 expres-
sion between TNF- and TWEAK-treated cells are responsible for
the seemingly superior TRAF1 induction by TWEAK, we ana-
lyzed TRAF1 stability in TNF- and TWEAK-stimulated cells. For
this purpose, cells were treated upon TRAF1 induction with the
proteasome inhibitor MG132 and the protein synthesis inhibitor
cycloheximide (CHX) (Figure 3A). As TNF has a weak apoptosis-
inducing effect on HT1080 cells, we investigated in this cell line
also the effect of the pan-caspase inhibitor z-VAD-fmk on TRAF1
induction (Figure 3B). However, we found no evidence in these
experiments that the aforementioned post-transcriptional mech-
anisms differentially limit TNF- and TWEAK-induced TRAF1
expression. Furthermore, more efficient TRAF1 induction by sol-
uble TWEAK was also evident from RT-PCR analysis of TNF- and
TWEAK-treated cells arguing again against a major role of post-
transcriptional mechanisms in TRAF1 production by TNF and
soluble TWEAK (Figures 3C,D).
SOLUBLE TWEAK INDUCES TRAF1 BY CLASSICAL NFκB
PATHWAY-DEPENDENT AND -INDEPENDENT MECHANISMS
The superior ability of soluble TWEAK compared to TNF to
induce TRAF1 as well as the kinetics of TWEAK-induced TRAF1
expression suggest that classical NFκB pathway-independent
mechanisms play here a crucial role. Indeed, oligomerization of
soluble TWEAK, a way to enhance the ability of soluble TWEAK
to stimulate the classical NFκB pathway, which, however, has prac-
tically no effect on the stimulation of the alternative NFκB pathway
(15), showed no major enhancing effect on TRAF1 induction
(Figure 4A). The ability of soluble TWEAK to induce the classical
NFκB target IL8, however, was strongly enhanced by oligomeriza-
tion (Figure 4B). As, on the one hand, oligomerization enhances
the ability of soluble TWEAK to trigger the classical NFκB path-
way, and as, on the other hand, oligomerization has no effect on
the dose response of TWEAK-induced TRAF1 induction, the latter
seems to be controlled to a significant extent by mechanisms inde-
pendent from classical NFκB signaling. In line with our previous
finding that oligomerized soluble TWEAK mimics the activity of
membrane TWEAK (15, 32), we furthermore observed that cells
expressing a non-cleavable mutant of membrane TWEAK effi-
ciently trigger IL8 and TRAF1 production, while soluble TWEAK
producing cells showed strong TRAF1 induction but only very
moderate IL8 induction (Figures 4C,D).
We have recently shown that TNF-induced IKK2-mediated
activation of the classical NFκB pathway is strongly inhibited
without a significant effect on TWEAK-induced IKK1-mediated
activation of the alternative NFκB pathway in cells treated with
the IKK2-specific inhibitor TPCA1 (33). Under such conditions,
TNF-induced TRAF1 production was blocked in all cell lines inves-
tigated (Figure 5A). In some cell lines, the minor levels of basal
TRAF1 expression were also reduced by treatment with TPCA1.
In these cases, TPCA1 treatment reduced TNF-induced TRAF1
FIGURE 3 | SolubleTWEAK is superior toTNF inTRAF1 mRNA induction.
(A,B) TRAF1 expression was induced in the indicated cell lines by overnight
stimulation with Flag-TWEAK (200 ng/ml) or Flag-TNF (100 ng/ml). Cells were
then treated for additional 4 h with the proteasome inhibitor MG132 (20µM)
and/or the protein synthesis inhibitor cycloheximide (25µg/ml). (B) HT1080
cells were stimulated overnight with TNF and TWEAK in the presence and
absence of z-VAD-fmk (20µM) and total cell lysates were analyzed by
western blotting for TRAF1 induction. (C,D) Total RNA was isolated from cells
stimulated with Flag-TNF (100 ng/ml) or Flag-TWEAK (200 ng/ml) overnight
and subjected to analysis by reverse transcriptase PCR (C) and quantitative
real time PCR. The average fold induction calculated from normalized data
derived of three fully independent experiments is shown (D).
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FIGURE 4 | Oligomerization of solubleTWEAK results in enhanced
induction of IL8 but has no major effect onTRAF1 induction and
alternative NFκB signaling. (A) Cells were stimulated overnight as
indicated with Flag-TWEAK and 1µg/ml of the Flag-specific mAb M2 and
TRAF1 expression in total cell lysates were analyzed by western blotting.
(B) Cells were stimulated in triplicates with increasing concentrations of
Flag-TWEAK in the presence and absence of M2 (1µg/ml). The next day,
supernatants were assayed for their IL8-content by ELISA. Prior
stimulation cell culture medium was replaced to reduce the background
caused by constitutive IL8 production. Please note, the decline in IL8
production observed at high concentrations of anti-Flag oligomerized
Flag-TWEAK presumably reflects suboptimal complex formation by M2
and Flag-TWEAK. (C,D) HT1080 cells were transiently transfected with the
indicated mixtures of expression plasmids encoding soluble Flag-TWEAK
(rec. sTWEAK) or a non-cleavable mutant of membrane TWEAK
(nc-memTWEAK) and empty vector. Next day, cells were harvested and
seeded in 6-well and 96-well plates. After an additional day, total lysates
derived of transfected cells (6-well) were analyzed by western blotting for
expression of the indicated proteins (C) and supernatants (triplicates) were
analyzed with respect to their IL8 and TWEAK content by ELISA (D).
expression to the level or even below the level of basal expression
of the untreated cells (Figure 5A). This emphasizes the efficacy
of the inhibitory effect of TPCA1 and indicates that basal TRAF1
expression is at least partly maintained in some cell lines by weak
constitutive classical NFκB signaling. The effect of TPCA1 on
TWEAK-induced TRAF1 production, however, varied dependent
on the cell line considered. TWEAK-induced TRAF1 expression
was fully inhibited in TPCA1-treated A172 cells and likewise in
IκBα-SR expressing A172 transfectants (Figures 5A,B). However,
in the other cell lines investigated there was only partial inhibition
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FIGURE 5 |The two NFκB signaling pathways are of varying cell
type-specific relevance forTWEAK-inducedTRAF1 expression. (A) Cells
were stimulated overnight with Flag-TWEAK (200 ng/ml) and Flag-TNF
(100 ng/ml) and total cell lysates were analyzed by western blotting for NIK
accumulation, p100 processing and expression of TRAF1, where indicated
cells were pretreated for 30 min with 10µM TPCA1. (B) Control vector and
IκBα-SR transduced A172 cells were stimulated overnight with increasing
concentrations of Flag-TWEAK and were assayed by western blotting of total
cell extracts for TRAF1 production and activation of the alternative NFκB
pathway (left panel). Efficacy of IκBα-SR-mediated repression of the classical
NFκB pathway was proved by analyzing phosphorylation and degradation of
IκBα in cells stimulated with TNF (100 ng/ml) (right panel). (C) The indicated
cell lines were pretreated or not with 10µM MLN4924 for 30 min and then
stimulated with Flag-TWEAK (200 ng/ml) and Flag-TNF (100 ng/ml). The next
day, total cell lysates were prepared and analyzed for the presence of the
indicated proteins by western blotting.
of TWEAK-induced TRAF1 expression by TPCA1 (Figure 5A).
This also argues for a capability of TWEAK to induce TRAF1
by classical NFκB pathway-independent mechanisms. Moreover,
in all cell lines analyzed, including those where soluble TWEAK
induces significant TRAF1 expression in the presence of TPCA1,
the NEDD8-activating enzyme (NAE)-inhibitor MLN4924 (34),
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which interferes with IκBα degradation and p100 processing
(33), inhibited upregulation of TRAF1 (Figure 5C). Although,
MLN4924 also targets other signaling pathways and the cell cycle,
this points to an important role of the alternative NFκB pathway
in soluble TWEAK-induced TRAF1 expression.
TWEAK PRIMING AND ECTOPIC TRAF1 EXPRESSION INTERFERE WITH
CD40 SIGNALING
We observed recently that priming of cells with soluble TWEAK
for a few hours strongly inhibits CD40 signaling and traced this
back to impaired formation of TRAF2–cIAP1/2 containing CD40
signaling complexes (20). Noteworthy, TRAF1 forms with high
efficiency heterotrimers with TRAF2 and this heteromeres inter-
act much stronger with cIAP2 than homotrimeric TRAF2 (21).
On the other side, however, there is evidence that TRAF1-TRAF2
heteromers bind weaker to CD40 than TRAF2 homotrimers (22).
To evaluate a possible role of TRAF1 induction in the crosstalk
of TWEAK and CD40, we took advantage of 786-O and U2-OS
cells that we have stably transfected for another project with a cas-
pase cleavage-resistant TRAF1 variant with unchanged protein–
protein interaction properties. In accordance with our previous
findings (20), priming with soluble TWEAK diminished CD40L-
induced upregulation of the classical NFκB-controlled cytokine
IL8 in U2-OS cells as well as induction of the likewise classical
NFκB-regulated cytokine IL6 in 786-O cells (Figure 6A).
More important, analysis of the TRAF1 transfectants
also revealed reduced CD40L-stimulated cytokine induction
(Figure 6A). A similar inhibitory effect of TWEAK priming and
ectopic TRAF1 expression was also evident from western blot
analysis of CD40L-induced phosphorylation and degradation of
IκBα. In accordance with the delayed weak activation of the clas-
sical NFκB pathway already observed in Figure 2B, 786-O and
U2-OS cells that were primed overnight with soluble TWEAK
showed increased levels of phosphorylated IκBα compared to
non-primed cells (Figure 6B). More important, however, while
rapid (5–15 min) CD40L-induced phosphorylation and degrada-
tion of IκBα were detectable in non-primed 786-O and U2-OS
cells, CD40 stimulation failed to trigger a significant reduction in
the IκBα levels in TWEAK-primed cells as well as in TRAF1 trans-
fectants. Moreover, there was no further CD40L-induced increase
in “basal” IκBα phosphorylation in the TWEAK-primed cells and
no or only a minor effect on IκBα phosphorylation in the TRAF1
transfectants (Figure 6B). As already observed earlier (20), prim-
ing with soluble TWEAK showed neither a major effect on CD40
cell surface expression nor on the affinity of CD40L for CD40
(Figures 6C,D). Similarly, TRAF1 transfectants showed no dis-
turbance of cell surface expression of CD40 and CD40L–CD40
interaction (Figures 6C,D). Thus, changes in CD40 expression
cannot explain the inhibitory effect of TWEAK priming and
ectopic TRAF1 expression on CD40 signaling.
DISCUSSION
The proteins of the NFκB family (RelA/p65, RelB, cRel, p50, and
p52) form homo- and heterodimeric transcription factors whose
nuclear translocation and activity are controlled by two prototypic
signaling pathways: the classical (canonical) and the alternative
(non-canonical) NFκB pathway (23, 35). In non-stimulated cells
NFκB dimers are retained in the cytoplasm either by interac-
tion with proteins of the IκB family or due to the activity of an
inhibitory domain, which is part of the p50 and p52 precursor
proteins p100 and p105. The classical NFκB pathway can be acti-
vated by various stimuli, including proinflammatory cytokines.
The latter initially trigger, with the help of E3 ligases TRAF2,
cIAP1, cIAP2, and TRAF6, activation of a subset of MAP3Ks,
e.g., MEKK3 and TAK1. These MAP3Ks stimulate then the IκB
kinase (IKK) complex, which is composed of the regulatory scaf-
fold protein IKKγ/NEMO and the kinases IKK1 and IKK2. IKK
complex-catalyzed phosphorylation of IκBs leads next to the ubiq-
uitination and proteasomal degradation of this inhibitory proteins
and thus to release and nuclear translocation of IκB-bound NFκB
dimers (35). The signaling events of the classical NFκB pathway
are fast and typically result in IκB degradation and NFκB nuclear
translocation in <1 h. Activation of the alternative NFκB pathway
is primarily stimulated by some TNF receptors and crucially bases
on the accumulation of the constitutively active MAP3K NIK. In
non-stimulated cells, there is ongoing proteasomal degradation of
NIK which is triggered by the concerted action of the aforemen-
tioned E3 ligases cIAP1, cIAP2, and TRAF2 and the TRAF2-related
E3 ligase TRAF3. Stimulation of TNF receptors that activate the
alternative NFκB pathway results in depletion and/or degradation
of the NIK inhibitory E3 ligases and thus in accumulation of NIK.
The latter now activates IKK1 and IKK1 in turn triggers process-
ing of p100 to p52 and nuclear translocation of the remaining p52
containing NFκB dimers (23).
NFκB-mediated induction of TRAF1 is well established for
a variety of inducers of the classical NFκB pathway, including
TNF, IL1, T-cell and B-cell receptor-stimulating antibodies, LPS,
and phorbol-12-myristate-13-acetate (PMA) (24–26, 36). Soluble
TWEAK furthermore has been recognized as poor inducer of genes
regulated by the classical NFκB pathway particular in comparison
with TNF [(12, 15, 32); see also Figure 1]. Against this background,
it was surprising to note in this study that soluble TWEAK is
superior to TNF in TRAF1 induction, although it barely induced
other classical NFκB-regulated genes, such as the gene encoding
IL8 (Figures 1 and 2). This suggests that soluble TWEAK utilizes
classical NFκB-independent mechanisms for TRAF1 induction. So
far the only Fn14-associated signaling events for which robust trig-
gering by soluble TWEAK had been demonstrated are depletion of
TRAF2–cIAP complexes along with stimulation of the alternative
NFκB pathway and enhancement of TNFR1-induced apoptosis
(15, 17). It is therefore tempting to speculate that the alterna-
tive NFκB pathway plays an important role in TWEAK-induced
TRAF1 expression. This idea is supported by several lines of evi-
dence. First, the kinetic of TWEAK-induced TRAF1 expression
is delayed in comparison to the kinetic of TRAF1 induction by
TNF and follows the activity of the alternative NFκB pathway
(Figure 2). Second, oligomerization of soluble TWEAK, which
converts soluble TWEAK trimers into a molecule species with
membrane TWEAK-like activity and thus a strongly enhanced
capacity to trigger the classical NFκB pathway, has no major effect
on TRAF1 induction although it leads to potentiation of induction
of IL8 (Figure 4). Third,p80HT,a lymphoma-associated truncated
mutant of p100 lacking parts of the inhibitory domain of the mol-
ecule, interacts with the TRAF1 promoter and induces TRAF1
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FIGURE 6 |TRAF1 expression interferes with CD40-induced signaling.
(A) U2OS and 786-O cells with and without TWEAK priming (200 ng/ml, 6 h)
and U2OS-TRAF1 and 786-O-TRAF1 transfectants were stimulated in 96-well
plates in triplicates with the indicated concentrations of Fc–Flag-CD40L.
Next day, supernatants were assayed for production of IL8 or IL6 by ELISA.
Prior stimulation cell culture medium was replaced to reduce the background
caused by constitutive cytokine production. (B) U2-OS and 786-O cells with
and without TWEAK priming and TRAF1 expressing U2-OS and 786-O
transfectants were stimulated with Fc–Flag-CD40L for 5 and 15 min and
were finally analyzed by western blotting to detect the indicated molecules.
Please note, in the case of the TRAF1 western blots a relatively short
exposure time is shown to ensure reasonable visibility of overexpressed and
TWEAK-induced TRAF1. (C) 786-O and U2-OS cells and their corresponding
TRAF1 transfectants were primed overnight with soluble TWEAK or
remained untreated and were then analyzed by FACS for CD40 cell surface
expression. (D) Cells (2×105 cells/well) were seeded in 24-well plates. Next
day, half of the samples of each cell type were pretreated for 1 h at 37°C
with 2µg/ml of Fc–Flag-CD40L. Next, untreated and Fc–Flag-CD40L
pretreated cells were incubated pairwise with increasing concentrations of
GpL–Fc–Flag-CD40L (1 h, 37°C), a fusion protein of Fc–Flag-CD40L with the
luciferase from Gaussia princeps. After removal of unbound CD40L
molecules, cells were scratched in 50µl medium to measure cell-associated
luciferase activity. Specific binding values were obtained by subtraction of
the non-specific binding values derived of Fc–Flag-CD40L pretreated cells
from the corresponding total binding values. Specific binding values were
fitted by non-linear regression using the GraphPad Prism5 software. Specific
binding values were normalized according to the maximum binding value
obtained from the linear regression.
www.frontiersin.org February 2014 | Volume 5 | Article 63 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carmona Arana et al. TRAF1 induction by soluble TWEAK
expression (37). Fourth, the IKK2-selective inhibitor TPCA1,
which only blocked activation of the classical NFκB pathway,
inhibited TNF-induced TRAF1 production completely but showed
in most cell lines, investigated here only a partial inhibitory effect
on TRAF1 expression (Figure 5A). In contrast, the NAE inhibitor
MLN4924, which inhibits signaling by both NFκB pathways, com-
pletely blocked TWEAK-induced TRAF1 expression (Figure 5C).
The results of the inhibitor studies indeed argue for a role of the
alternative NFκB pathway in TWEAK-induced TRAF1 expression
but also point to a contribution of the classical NFκB pathway. This
becomes particularly evident in the A172 cell line where TWEAK-
induced TRAF1 production was completely abrogated by TPCA1
treatment (Figure 5A) or IκBα-SR expression (Figure 5B) despite
poor activation of the classical NFκB pathway (Figure 1). In sum,
our data suggest that both the classical and the alternative NFκB
pathway act together to realize the strong induction of TRAF1
by TWEAK. In this context, it is worth mentioning that various
cross-talk mechanisms have been identified in the recent years
that link the two NFκB signaling pathways. These mechanisms
reach from NIK- and IKK1-mediated phosphorylation of IκBα
(27) over phosphorylation and transactivation of c-Rel by NIK
(38) to IKK1-mediated chromatin remodeling (39, 40). Moreover,
the NIK/IKK1-regulated p52 precursor protein p100 can inhibit
NFκB dimers intermolecularly with the result that NFκB dimers,
which are actually regulated by the classical pathway, come under
the control of the alternative pathway (41).
We and others have observed that priming with soluble TWEAK
for a few hours can induce a state of reduced responsiveness
for proinflammatory signaling by TNFR1, TNFR2, and CD40
in a variety of cell lines and cell types including adipocytes
and fibroblast-like synoviocytes of patients suffering on rheuma-
toid arthritis [(17, 18–20); see also Figure 6]. Although, the
molecular basis of the desensitizing effect of soluble TWEAK
has not been intensively studied so far, there is good evidence
that TWEAK-induced Fn14-mediated depletion of cytosolic com-
plexes of TRAF2 and cIAP1/2 plays a major role by limiting the
availability of these proteins for the aforementioned receptors. For
example, TRAF2 and cIAPs are recruited to the TNFR1 signaling
complex and are required there for ubiquitination of RIP and
subsequent recruitment of the classical NFκB-stimulating IKK
complex [for review, see (42)]. However, recruitment of TRAF2
and especially of the TRAF2-interacting cIAPs and the IKK com-
plex to the TNFR1 signaling complex as well as RIP ubiquitina-
tion are severely reduced in TWEAK-primed cells (17). Reduced
recruitment of cIAP1 and cIAP2 and the IKK complex along
with reduced classical NFκB signaling in TWEAK-primed cells
have also been observed for TNFR2 (20). Depletion of cytosolic
TRAF2–cIAP1/2 complexes straightforwardly explains the desen-
sitizing effect of soluble TWEAK on activation of the classical
NFκB pathway by TNFR1, TNFR2, and CD40 because all these
receptors exploit TRAF2 and the cIAPs for activation of this path-
way (4, 42). In the case of CD40, however, there is evidence
for an additional mechanism. Immunoprecipitation of ligand-
associated receptor signaling complexes in TWEAK-primed cells
resulted for TNFR1 and TNFR2 in practically unchanged amounts
of co-precipitated receptor and only showed a reduction in the
amount of co-precipitated TRAF2, cIAPs, and IKK molecules (17,
20). In contrast, CD40L immunoprecipitates of TWEAK-primed
cells contained only minor amounts of co-immunoprecipitated
CD40 despite unchanged CD40 expression and normal CD40L–
CD40 interaction on intact cells (20). It is thus tempting to
speculate that TRAF2 trimers “crosslink” neighboring CD40L–
CD40 complexes and that this result in supramolecular CD40–
CD40L clusters that counteract the dissociation of CD40–CD40L
complexes in the disintegrated cell during immunoprecipitation.
Indeed, previous findings showed that CD40 poorly interacts
with TRAF2–TRAF1 heteromers and preferentially binds TRAF2
homotrimers whereas TNFR1 and TNFR2 recruit TRAF2–TRAF1
heteromers with high efficacy. Against the background that we
observed strong induction of TRAF1 already by soluble TWEAK
(Figures 1–3), it appears possible that soluble TWEAK-induced
TRAF1 expression affects recruitment of TRAF2 to CD40 and
the formation/stability of supramolecular CD40L–CD40 clus-
ters. Indeed, it has been found that TRAF1 and TRAF2 pref-
erentially form TRAF11–TRAF22 heterotrimers and that these
TRAF11–TRAF22 heterotrimers have a significantly higher affin-
ity for cIAP2 than TRAF2 homotrimers (21). The favored for-
mation of TRAF11–TRAF22–cIAP complexes along with their
weak affinity for CD40 might result in reduced recruitment
of cIAP-containing TRAF complexes to CD40 and could fur-
ther enhance the effect of Fn14-mediated depletion of TRAF2-
containing complexes. As TRAF2–TRAF1 heteromers strongly
interact with TNFR2 and TNFR1-associated TRADD [e.g., Ref.
(43)] this mechanism would not be of relevance for the crosstalk
of TWEAK with TNFR1 and TNFR2. In line with the set fourth
hypothesis, we observed in this study that ectopic expression of
TRAF1 has principally a similar effect on CD40 signaling as prim-
ing with soluble TWEAK. Both TWEAK priming and ectopic
TRAF1 expression inhibited CD40L-induced activation of the
classical NFκB pathway (Figures 6A,B) without disturbing CD40
expression (Figure 6C) or CD40L–CD40 interaction [Ref. (20)
and Figure 6D].
MATERIALS AND METHODS
CELL LINES AND REAGENTS
The human renal cell carcinoma cell line 786-O, the human
osteosarcoma cell line U2-OS, the human fibrosarcoma cell line
HT1080 were from the American Tissue Culture Collection. The
human ovarian cancer cell line OAW-42 were from the European
Typical Culture Collection and vector and IκBα-SR transduced
A172 cells were a kind gift of Prof. Simone Fulda (University
of Frankfurt) that has been characterized in detail elsewhere
(44). With exception of 786-O cells, all cells were cultivated in
RPMI1640 medium (Sigma) supplemented with 10% fetal calf
serum (Invitrogen). 786-O cells were maintained in 10% FCS
supplemented DMEM (Sigma). The characterization of HT1080-
CD40 transfectants as well as cloning, production, and purifica-
tion of Flag-TWEAK, Flag-TNF, and Fc–Flag-CD40L have been
described elsewhere (15, 45). MG132 and cycloheximide were
purchased from Sigma and z-VAD-fmk from Bachem. Human
skeletal muscle progenitor cells including growth medium and
supplements were from PeloBiotech GmbH and hMSCs were
a kind gift from Dr. Joachim Nickel (University Hospital of
Würzburg).
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TRANSFECTION OF HT1080 CELLS
HT1080 cells were transfected with expression plasmids encod-
ing Flag-tagged soluble TWEAK (Flag-sTWEAK) or non-cleavable
full-length TWEAK (nc-memTWEAK) harboring mutations
(R80A–R93A–R97A) that strongly reduce processing by furin pro-
teases using Lipofectamine according to the suppliers protocol
(Invitrogen). Next day, cells were harvested and seeded in 6-well
and 96-well plates. After an additional day, cells from 6-wells were
used for western blot analysis of total cell lysates and cell culture
supernatants of cells cultivated in 96-well plates were subjected to
ELISA to determine the content of IL8 (see below) and soluble
TWEAK (ELISA Duo Set; R&D Systems).
EQUILIBRIUM BINDING STUDIES WITH GpL–Flag-CD40L
The interaction of CD40L with cell surface expressed CD40 was
investigated by equilibrium binding studies at 37°C with a Gaus-
sia princeps luciferase (GpL) fusion protein of Fc–Flag-CD40L as
recently described elsewhere (20).
WESTERN BLOTTING
For analysis of NIK accumulation, p100 to p52 processing, expres-
sion of TRAF1 and TWEAK, and phosphorylation and degra-
dation of IκBα cells were washed once with PBS, harvested
using a rubber policeman, centrifuged, and then directly lysed
in 4× Laemmli sample buffer (approximately 1× 106 cells per
100µl buffer; 5 min, 95°C) supplemented with complete protease
inhibitor from Roche Applied Science and phosphatase inhibitor
mixtures I and II from Sigma. Lysates were sonicated for 15 s with
maximum amplitude (UP100H Ultrasonic Processor, Hielscher,
Germany), heated for 5 min at 95°C and centrifuged for 3 min
(Eppifuge, full speed) to remove residual insoluble debris. Lysates
were further processed using standard protocols for SDS-PAGE
and immunoblotting using horse radish peroxidase-conjugated
secondary antibodies (Dako) and the ECL Western blotting detec-
tion reagents and analysis system (Amersham). Primary antibodies
used were anti-IκBα (clone C35A5, Cell Signaling), anti-pIκBα
(clone 14D4, Cell Signaling), anti-NIK (#4994, Cell Signaling),
anti-p100/p52 (#05-361, Upstate), anti-TRAF1 (H-132, Santa
Cruz), anti-TWEAK (#AF1090, R&D Systems,) and anti-tubulin
(clone DM1A, Neomarker).
RT-PCR AND qPCR
Total RNA was purified using the RNeasy Mini kit from Qiagen
according to the protocol of the supplier. For reverse transcrip-
tion PCR, 1µg of total RNA were used to synthesize cDNA with
the QuantiTect Reverse Transcription kit (Qiagen) which were
then subjected to conventional PCR using the TRAF1-specific
primers 5′-GCCCCTGATGAGAATGAGTT-3′ (forward) and 5′-
CCTGGTGACATTGGTGATCTT-3′ (rewind) and the following
program: I. 95°C, 2 min; II. 20 s at 95°C followed by 60 s at 63°C
and 45 s at 70°C; III. 5 min, 72°C. For quantitative real time PCR
2% of the reverse transcription PCR reaction obtained with 1µg
total RNA were subjected to real time PCR using the BioRad
Cycler CT1000 with the CFX96 Real Time System and the Quan-
tiTect SYBR Green PCR Kit (Qiagen). Following program was
used: I. 95°C, hot start; II. 40 Cycles of 15 s at 95°C followed
by 30 s at 52°C and 30 s at 72°C and a sample without cDNA
served as a negative control. TRAF1 primers used for amplifi-
cation were 5′-CATGAGAGGGGAGTATGATG-3′ (forward) and
5′-GAAGAAGAGTGGGCATCCAC-3′ (rewind). PCR Amplifica-
tion of ß-actin using commercially available primers (Qiagen) was
used for normalization. Fold-induction values for TRAF1 were cal-
culated as follows: the CT-values of the β-actin PCR reactions of
the TNF and TWEAK-treated samples were set to the CT-value
of the β-actin PCR reaction of the cDNA derived of untreated
cells. The differences between the latter and the CT-values of the
β-actin PCR reactions of the TNF and TWEAK-treated samples
were furthermore used to correct the corresponding CT-values
of the TRAF1 PCR reactions. The differences between the cor-
rected CT-values of the untreated and TNF- or TWEAK-treated
samples (∆CT) were finally transformed into fold induction (fold
induction= 2∆CT).
ANALYSIS OF IL8/IL6 PRODUCTION
Cells were seeded with a density of 2× 104 cells/well in 96-well
tissue cultures plates and cultivated for a day. To reduce the
background of basal IL8 production, medium was replaced by
fresh medium prior overnight stimulation with Flag-TNF or Flag-
TWEAK. Supernatants were cleared by centrifugation and assayed
for IL8/IL6-production by help of the BD OptEIA Human IL8
ELISA Kit or the BD OptEIA Human IL6 ELISA Kit according to
the protocol of the manufacturer (BD Biosciences).
STATISTICAL ANALYSES
Statistical analyses were performed with the help of the program
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Error bars shown in ELISA and RT-PCR experiments represent the
standard error of mean (SEM) of triplicates. ELISA data shown
are representative for two or more independent experiments. The
comprehensive side by side analyses of the dose response and
kinetics of TNF- and TWEAK-induced TRAF1 expression were
performed only once for most cell lines whereby the basic findings
(no enhancing effect of oligomerization of soluble TWEAK, com-
parable or stronger TRAF1-inducing activity of soluble TWEAK
compared to TNF) were previously observed in two or more
experiments with slightly varying conditions (stimulation time,
concentrations used for stimulation, and the like).
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